Ads
related to: timolol maleate 0.5% ophthalmic solution spray- Appropriate Patient Types
View The Appropriate Patient Types
That May Benefit From VYZULTA.
- Dosing Information
Learn How This Treatment's
Dosing May Help Your Patients.
- Real World Studies
View Real World Studies Data To See
How VYZULTA May Help Your Patients.
- Tolerability Data
Explore The Tolerability Data From
VYZULTA Phase 3 Trials.
- Appropriate Patient Types
Search results
Results From The WOW.Com Content Network
The IOP is higher during sleep. Efficacy of timolol in lowering IOP during the sleep period may be limited. [16] [17] [18] It is a 5–10× more potent beta blocker than propranolol. Timolol is light-sensitive; it is usually preserved with 0.01% benzalkonium chloride (BAC), but also comes BAC-free.
Two prospective, randomized, double-blinded, phase III clinical trials were conducted at 53 sites in the United States to compare the IOP-lowering efficacy and safety of 0.2% brimonidine tartrate/0.5% timolol maleate fixed combination twice daily with 0.2% brimonidine tartrate three times daily or 0.5% timolol maleate twice daily in patients ...
Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. [3] [5] [6] It is a combination of dorzolamide hydrochloride and timolol maleate. [3] It may be used when a beta blocker, like timolol, is not sufficient alone. [7] It is used as an eye drop. [3]
[4] [5] It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate. [6] Common side effects when used in the eyes include itchiness, redness, and a dry mouth. [4] Common side effects when used on the skin include redness, burning, and headaches. [5]
"Timolol maleate mixture with Travoprost". Drug Information Portal. U.S. National Library of Medicine. This page was last edited on 31 October 2023, at 11:22 ...
Latanoprost is more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials. Latanoprost demonstrated a stable long-term IOP-lowering effect in 1- or 2-year continuations of these trials, with no sign of diminishing effect during prolonged treatment.
Ad
related to: timolol maleate 0.5% ophthalmic solution spray